NCT07088445View on ClinicalTrials.gov

Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Neovascular Age-related Macular Degeneration(nAMD)

Interventions

DRUG

Faricimab

Intravitreal injection of 6mg famotizumab into the vitreous cavity of patients with non primary wet age-related macular degeneration

All Listed Sponsors

lead

Hui Peng

OTHER

NCT07088445 - Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter